Progeria, rapamycin and normal aging: recent breakthrough
2011
Rapamycin and Aging: Insights from Progeria
publication
Evidence: moderate
Author Information
Author(s): Mikhail V. Blagosklonny
Primary Institution: Roswell Park Cancer Institute
Hypothesis
Can rapamycin serve as a non-toxic therapy for progeria and normal aging?
Conclusion
Rapamycin shows promise in treating progeria and may also have implications for normal aging.
Supporting Evidence
- Rapamycin decreases levels of progerin, preventing telomere erosion.
- Rapamycin is indicated for prevention of age-related diseases including cancer.
- Rapamycin can improve responses to infections as an immunostimulator.
Takeaway
Rapamycin is a drug that might help kids with a rare aging disease and could also help older people live longer.
Limitations
The study does not provide direct evidence for the effectiveness of rapamycin in humans with progeria.
Want to read the original?
Access the complete publication on the publisher's website